Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms
- PMID: 16826219
- DOI: 10.1038/ncponc0538
Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms
Abstract
Cell death is a normal facet of human physiology, ensuring tissue homeostasis by offsetting cell production with cell demise. Neoplasms arise in part because of defects in physiological cell death mechanisms, contributing to pathological cell expansion. Defects in normal cell death pathways also contribute to cancer progression by permitting progressively aberrant cell behaviors, while also desensitizing tumor cells to immune-mediated attack, radiation, and chemotherapy. Through basic research, much has been learned about the molecular mechanisms responsible for cell turnover and how tumors escape cell death. By exploiting this knowledge base, several innovative strategies for eradicating malignancies have materialized that are based on restoration of natural pathways for cell autodestruction. Some of these strategies have advanced into human clinical trials. Several of the current strategies based on targeting core components of the cell death machinery for cancer therapy are reviewed here, and a summary of progress toward clinical applications is provided.
Similar articles
-
Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic.Klin Padiatr. 2009 Nov-Dec;221(6):332-8. doi: 10.1055/s-0029-1241178. Epub 2009 Nov 4. Klin Padiatr. 2009. PMID: 19890783 Review.
-
Selective anticancer strategies via intervention of the death pathways relevant to cell transformation.Cell Death Differ. 2008 Aug;15(8):1197-210. doi: 10.1038/cdd.2008.48. Epub 2008 Apr 25. Cell Death Differ. 2008. PMID: 18437165 Review.
-
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).J Clin Oncol. 2008 Jul 20;26(21):3621-30. doi: 10.1200/JCO.2007.15.7198. J Clin Oncol. 2008. PMID: 18640940 Review.
-
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.Oncogene. 2008 Oct 20;27(48):6207-15. doi: 10.1038/onc.2008.298. Oncogene. 2008. PMID: 18931688 Review.
-
Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia.Br J Haematol. 2009 May;145(4):441-54. doi: 10.1111/j.1365-2141.2009.07603.x. Br J Haematol. 2009. PMID: 19298593 Review.
Cited by
-
miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.Med Oncol. 2012 Mar;29(1):384-91. doi: 10.1007/s12032-010-9797-4. Epub 2011 Jan 22. Med Oncol. 2012. PMID: 21258880
-
The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage.Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1093-8. doi: 10.1073/pnas.0808173106. Epub 2009 Jan 14. Proc Natl Acad Sci U S A. 2009. PMID: 19144918 Free PMC article.
-
BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.Clin Cancer Res. 2009 Jan 1;15(1):150-9. doi: 10.1158/1078-0432.CCR-08-1575. Clin Cancer Res. 2009. PMID: 19118042 Free PMC article.
-
TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP.Oncogene. 2009 Jun 11;28(23):2257-65. doi: 10.1038/onc.2009.110. Epub 2009 May 4. Oncogene. 2009. PMID: 19421137 Free PMC article.
-
Immunogenic Cell Death Role in Urothelial Cancer Therapy.Curr Oncol. 2022 Sep 18;29(9):6700-6713. doi: 10.3390/curroncol29090526. Curr Oncol. 2022. PMID: 36135095 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources